PMID- 34414939 OWN - NLM STAT- MEDLINE DCOM- 20210902 LR - 20210902 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 100 IP - 33 DP - 2021 Aug 20 TI - Elevated homocysteine levels in patients with heart failure: A systematic review and meta-analysis. PG - e26875 LID - 10.1097/MD.0000000000026875 [doi] LID - e26875 AB - BACKGROUND: Elevated homocysteine (Hcy) levels showed increasing significance as the predisposing factor for the pathogenesis of atherosclerotic sequelae, including cardiovascular mortality, coronary artery disease, and stroke. There is increasing evidence linking plasma Hcy levels and heart failure (HF). The association between the elevated level of plasma Hcy and HF was examined by meta-analysis and systematic review in this study. METHODS: The PubMed and ScienceDirect databases until April 2020 were utilized to collect previous literature on plasma Hcy levels and the potential relation to HF. The pooled effects were evaluated depending on standardized mean differences (SMDs) with 95% confidence intervals (CIs), and the calculation was performed using Stata 12 software. Potential sources of heterogeneity were assessed with subgroup analysis and sensitivity analysis. RESULTS: A total of 12 research projects including 5506 subjects were selected. For pooled effect, the results confirmed that patients with HF had higher Hcy levels than the control subjects (SMD,1.148 and 95%CI, [0.715, 1.581]). Based on the classification of New York Heart Association (NYHA), the Hcy levels for the group of NYHA I or II (SMD, 1.484 and 95% CI, [0.442, 2.527]) and the group of NYHA III or IV (SMD, 3.361 and 95% CI, [1.902, 4.820]) were significantly increased compared to controls, while the increase was more intensive for the group of NYHA III or IV. Subgroup analyses revealed similar results. CONCLUSION: Our meta-analysis identified that plasma Hcy levels were significantly elevated in HF patients compared to control subjects, which is positively related to the advancement of NYHA class. CI - Copyright (c) 2021 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Jin, Nake AU - Jin N AD - Department of Cardiology, Ningbo Hangzhou Bay Hospital, Ningbo, China. FAU - Huang, Lei AU - Huang L AUID- ORCID: 0000-0002-6626-459 AD - Department of Cardiology, Ningbo Hangzhou Bay Hospital, Ningbo, China. FAU - Hong, Jun AU - Hong J AD - Department of Cardiology, Ningbo Hangzhou Bay Hospital, Ningbo, China. FAU - Zhao, Xuechen AU - Zhao X AD - Department of Cardiology, Ningbo Hangzhou Bay Hospital, Ningbo, China. FAU - Chen, Yujiao AU - Chen Y AD - Department of Cardiology, Ningbo Hangzhou Bay Hospital, Ningbo, China. FAU - Hu, Jianan AU - Hu J AD - Department of Cardiology, Ningbo Hangzhou Bay Hospital, Ningbo, China. FAU - Cong, Xin AU - Cong X AD - Department of Cardiology, Ningbo Hangzhou Bay Hospital, Ningbo, China. FAU - Xie, Yuquan AU - Xie Y AD - Department of Cardiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. FAU - Pu, Jun AU - Pu J AD - Department of Cardiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. LA - eng GR - 2019Y26/Ningbo Medical Science and Technology Project/ PT - Journal Article PT - Meta-Analysis PT - Systematic Review PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R RN - 0LVT1QZ0BA (Homocysteine) SB - IM MH - Heart Failure/*blood/*complications MH - Homocysteine/*blood MH - Humans PMC - PMC8376397 COIS- The authors have no conflicts of interest to disclose. EDAT- 2021/08/21 06:00 MHDA- 2021/09/03 06:00 PMCR- 2021/08/20 CRDT- 2021/08/20 09:05 PHST- 2021/04/18 00:00 [received] PHST- 2021/07/22 00:00 [accepted] PHST- 2021/08/20 09:05 [entrez] PHST- 2021/08/21 06:00 [pubmed] PHST- 2021/09/03 06:00 [medline] PHST- 2021/08/20 00:00 [pmc-release] AID - 00005792-202108200-00009 [pii] AID - MD-D-21-02817 [pii] AID - 10.1097/MD.0000000000026875 [doi] PST - ppublish SO - Medicine (Baltimore). 2021 Aug 20;100(33):e26875. doi: 10.1097/MD.0000000000026875.